Noninvasive evaluation of NAFLD

Nature Reviews Gastroenterology and Hepatology

Volumn 10, Issue 11, 2013, Pages 666-675

  Castera, Laurent ^a,b,c   Vilgrain, Valérie ^a,b,c   Angulo, Paul ^a,b,c  

^a BEAUJON HOSPITAL   (France)

^b CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

^c UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CASPASE 3; CHOLESTEROL; CYTOKERATIN 18; GAMMA GLUTAMYLTRANSFERASE; TRIACYLGLYCEROL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL EVALUATION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DISEASE MARKER; DISEASE SEVERITY; ECHOGRAPHY; ELASTOGRAPHY; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; IMAGE ANALYSIS; LIPID STORAGE; LIVER FIBROSIS; NON INVASIVE PROCEDURE; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY; REVIEW; SENSITIVITY AND SPECIFICITY; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

DIAGNOSIS, DIFFERENTIAL; ELASTICITY IMAGING TECHNIQUES; FATTY LIVER; HUMANS; LIVER CIRRHOSIS; ULTRASONOGRAPHY;

EID: 84887321522     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2013.175     Document Type: Review

References (116)

1. Angulo, P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 346, 1221-1231 (2002).
2. Castera, L. & Pinzani, M. Non-invasive assessment of liver fibrosis: are we ready? Lancet 375, 1419-1420 (2010).
3. Hamer, O. W. et al. Fatty liver: imaging patterns and pitfalls. Radiographics 26, 1637-1653 (2006).
4. Schwenzer, N. F. et al. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J. Hepatol. 51, 433-445 (2009).
5. Webb, M. et al. Diagnostic value of a computerized hepatorenal index for sonographic quantification of liver steatosis. AJR Am. J. Roentgenol. 192, 909-914 (2009).
6. Ratziu, V., Bellentani, S., Cortez-Pinto, H., Day, C. & Marchesini, G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J. Hepatol. 53, 372-384 (2010).
7. Sasso, M. et al. Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med. Biol. 36, 1825-1835 (2010).
8. de Ledinghen, V., Vergniol, J., Foucher, J., Merrouche W. & le Bail, B. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int. 32, 911-918 (2012).
9. Myers, R. P. et al. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int. 32, 902-910 (2012).
10. Sasso, M. et al. Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan((R.)): validation in chronic hepatitis C. J. Viral Hepat. 19, 244-253 (2012).
11. Friedrich-Rust, M. et al. Acoustic radiation force impulse-imaging and transient elastography for non-invasive assessment of liver fibrosis and steatosis in NAFLD. Eur. J. Radiol. 81, e325-e331 (2012).
12. Masaki K. et al. Utility of controlled attenuation parameter measurement for assessing liver steatosis in Japanese patients with chronic liver diseases. Hepatol. Res. http://dx.doi.org/10.1111/hepr.12094.
13. Saadeh, S. et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 123, 745-750 (2002).
14. Szczepaniak, L. S. et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am. J. Physiol. Endocrinol. Metab. 288, E462-E468 (2005).
15. Wong, V. W. et al. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut 61, 409-415 (2012).
16. Dixon, W. T. Simple proton spectroscopic imaging. Radiology 153, 189-194 (1984).
17. Guiu, B. et al. Quantification of liver fat content: comparison of triple-echo chemical shift gradient-echo imaging and in vivo proton MR spectroscopy. Radiology 250, 95-102 (2009).
18. Lee, S. S. et al. Non-invasive assessment of hepatic steatosis: prospective comparison of the accuracy of imaging examinations. J. Hepatol. 52, 579-585 (2010).
19. van Werven, J. R. et al. Assessment of hepatic steatosis in patients undergoing liver resection: comparison of US, CT, T1-weighted dual-echo MR imaging, and point-resolved 1H MR spectroscopy. Radiology 256, 159-168 (2010).
20. Poynard, T. et al. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp. Hepatol. 4, 10 (2005).
21. Bedogni, G. et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 6, 33 (2006).
22. Bedogni, G., Kahn, H. S., Bellentani, S. & Tiribelli, C. A simple index of lipid overaccumulation is a good marker of liver steatosis. BMC Gastroenterol. 10, 98 (2010).
23. Kotronen, A. et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology 137, 865-872 (2009).
24. Lee, J. H. et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig. Liver Dis. 42, 503-508 (2010).
25. Dam-Larsen, S. et al. Final results of a long-term, clinical follow-up in fatty liver patients. Scand. J. Gastroenterol. 44, 1236-1243 (2009).
26. Ekstedt, M. et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44, 865-873 (2006).
27. Angulo, P. Long-term mortality in nonalcoholic fatty liver disease: is liver histology of any prognostic significance? Hepatology 51, 373-375 (2010).
28. Younossi, Z. M. et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology 53, 1874-1882 (2011).
29. Zardi, E. M. et al. Which clinical and sonographic parameters may be useful to discriminate NASH from steatosis? J. Clin. Gastroenterol. 45, 59-63 (2011).
30. Suzuki, K. et al. Measurement of spleen volume is useful for distinguishing between simple steatosis and early-stage non-alcoholic steatohepatitis. Hepatol Res. 40, 693-700 (2010).
31. Chen, J. et al. Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. Radiology 259, 749-756 (2011).
32. Poynard, T. et al. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 6, 34 (2006).
33. Palekar, N. A., Naus, R., Larson, S. P., Ward, J. & Harrison, S. A. Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease. Liver Int. 26, 151-156 (2006).
34. Shimada, M. et al. Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis. Am. J. Gastroenterol. 102, 1931-1938 (2007).
35. Wieckowska, A. et al. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 44, 27-33 (2006).
36. Feldstein, A. E. et al. Cytokeratin?18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 50, 1072-1078 (2009).
37. Alkhouri, N., Carter-Kent, C. & Feldstein, A. E. Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications. Expert Rev. Gastroenterol. Hepatol. 5, 201-212 (2011).
38. Shen, J. et al. Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. J. Hepatol. 56, 1363-1370 (2012).
39. Sandrin, L. et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med. Biol. 29, 1705-1713 (2003).
40. Roulot, D. et al. Liver stiffness values in apparently healthy subjects: Influence of gender and metabolic syndrome. J. Hepatol. 48, 606-613 (2008).
41. Castera, L., Forns, X. & Alberti, A. Non-invasive evaluation of liver fibrosis using transient elastography. J. Hepatol. 48, 835-847 (2008).
42. Castera, L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology 142, 1293-1302.e4 (2012).
43. Yoneda, M. et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig. Liver Dis. 40, 371-378 (2008).
44. Nobili, V. et al. Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology 48, 442-448 (2008).
45. Wong, V. W. et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 51, 454-462 (2010).
46. Lupsor, M. et al. Performance of unidimensional transient elastography in staging non-alcoholic steatohepatitis. J. Gastrointestin. Liver Dis. 19, 53-60 (2010).
47. Petta, S. et al. Reliability of liver stiffness measurement in non-alcoholic fatty liver disease: the effects of body mass index. Aliment. Pharmacol. Ther. 33, 1350-1360 (2011).
48. Gaia, S. et al. Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis. J. Hepatol. 54, 64-71 (2011).
49. Myers, R. P. et al. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology 55, 199-208 (2012).
50. Wong, V. W. et al. Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am. J. Gastroenterol. 107, 1862-1871 (2012).
51. Ransohoff, D. F. & Feinstein, A. R. Problems of spectrum and bias in evaluating the efficacy of diagnostic tests. N. Engl. J. Med. 299, 926-930 (1978).
52. Poynard, T. et al. Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. Clin. Chem. 53, 1615-1622 (2007).
53. Castera, L. et al. Pitfalls of liver stiffness measurement: A 5?year prospective study of 13,369 examinations. Hepatology 51, 828-835 (2010).
54. Wong, G. L. et al. Factors associated with unreliable liver stiffness measurement and its failure with transient elastography in the Chinese population. J. Gastroenterol. Hepatol. 26, 300-305 (2011).
55. Friedrich-Rust, M. et al. Transient elastography with a new probe for obese patients for non-invasive staging of non-alcoholic steatohepatitis. Eur. Radiol. 20, 2390-2396 (2010).
56. de Ledinghen, V. et al. Feasibility of liver transient elastography with FibroScan using a new probe for obese patients. Liver Int. 30, 1043-1048 (2010).
57. de Ledinghen, V. et al. Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan. J. Hepatol. 56, 833-839 (2012).
58. Coco, B. et al. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. J. Viral Hepat. 14, 360-369 (2007).
59. Sagir, A., Erhardt, A., Schmitt, M. & Haussinger, D. Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage. Hepatology 47, 592-595 (2007).
60. Arena, U. et al. Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology 47, 380-384 (2008).
61. Millonig, G. et al. Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis. Hepatology 48, 1718-1723 (2008).
62. Millonig, G. et al. Liver stiffness is directly influenced by central venous pressure. J. Hepatol. 52, 206-210 (2010).
63. Mederacke, I. et al. Food intake increases liver stiffness in patients with chronic or resolved hepatitis C virus infection. Liver Int. 29, 1500-1506 (2009).
64. Arena, U. et al. Liver stiffness is influenced by a standardized meal in patients with chronic HCV hepatitis at different stages of fibrotic evolution. Hepatology 58, 65-72 (2013).
65. Berzigotti, A. et al. Effect of meal ingestion on liver stiffness in patients with cirrhosis and portal hypertension. PLoS ONE 8, e58742 (2013).
66. Berzigotti, A. & Castera, L. Update on Ultrasound Imaging of Liver Fibrosis. J. Hepatol. 58, 180-182 (2013).
67. Nightingale, K., Soo, M. S., Nightingale, R. & Trahey, G. Acoustic radiation force impulse imaging: in vivo demonstration of clinical feasibility. Ultrasound Med. Biol. 28, 227-235 (2002).
68. Palmeri, M. L. et al. Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease. J. Hepatol. 55, 666-672 (2011).
69. Yoneda, M. et al. Nonalcoholic fatty liver disease: US?based acoustic radiation force impulse elastography. Radiology 256, 640-647 (2010).
70. Ochi, H. et al. Real-time tissue elastography for evaluation of hepatic fibrosis and portal hypertension in nonalcoholic fatty liver diseases. Hepatology 56, 1271-1278 (2012).
71. Muthupillai, R. et al. Magnetic resonance elastography by direct visualization of propagating acoustic strain waves. Science 269, 1854-1857 (1995).
72. Talwalkar, J. A. et al. Magnetic resonance imaging of hepatic fibrosis: emerging clinical applications. Hepatology 47, 332-342 (2008).
73. Kim, D., Kim, W. R., Talwalkar, J. A., Kim, H. J. & Ehman, R. L. Advanced fibrosis in nonalcoholic fatty liver disease: noninvasive assessment with MR elastography. Radiology 268, 411-419 (2013).
74. Huwart, L. et al. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology 135, 32-40 (2008).
75. Schuppan, D. & Afdhal, N. H. Liver cirrhosis. Lancet 371, 838-851 (2008).
76. Sheth, S. G., Flamm, S. L., Gordon, F. D. & Chopra, S. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am. J. Gastroenterol. 93, 44-48 (1998).
77. Angulo, P., Keach, J. C., Batts, K. P. & Lindor, K. D. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 30, 1356-1362 (1999).
78. Kruger, F. C. et al. APRI: a simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with NAFLD/NASH. S. Afr. Med. J. 101, 477-480 (2011).
79. Chitturi, S. et al. HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology 36, 142-149 (2002).
80. Bugianesi, E. et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 39, 179-187 (2004).
81. Manousou, P. et al. Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients. Liver Int. 31, 730-739 (2011).
82. Angulo, P. et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45, 846-854 (2007).
83. Dixon, J. B., Bhathal, P. S. & O'Brien, P. E. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 121, 91-100 (2001).
84. Harrison, S. A., Oliver, D., Arnold, H. L., Gogia, S. & Neuschwander-Tetri, B. A. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 57, 1441-1447 (2008).
85. Marceau, P. et al. Liver pathology and the metabolic syndrome X in severe obesity. J. Clin. Endocrinol. Metab. 84, 1513-1517 (1999).
86. Miyaaki, H. et al. Clinicopathological study of nonalcoholic fatty liver disease in Japan: the risk factors for fibrosis. Liver Int. 28, 519-524 (2008).
87. Ratziu, V. et al. Liver fibrosis in overweight patients. Gastroenterology 118, 1117-1123 (2000).
88. Adams, L. A. et al. Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease. J. Gastroenterol. Hepatol. 26, 1536-1543 (2011).
89. Cales, P. et al. Comparison of blood tests for liver fibrosis specfic or not specific to NAFLD. J. Hepatol. 50, 165-173 (2009).
90. Shah, A. G. et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 7, 1104-1112 (2009).
91. Adams, L. A. et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin. Chem. 51, 1867-1873 (2005).
92. Qureshi, K., Clements, R. H. & Abrams, G. A. The utility of the NAFLD fibrosis score in morbidly obese subjects with NAFLD. Obes. Surg. 18, 264-270 (2008).
93. Wong, V. W. et al. Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis. Am. J. Gastroenterol. 103, 1682-1688 (2008).
94. Chalasani, N. et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 142, 1592-1609 (2012).
95. Guha, I. N. et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 47, 455-460 (2008).
96. Kaneda, H., Hashimoto, E., Yatsuji, S. & Tokushige, K., Shiratori, K. Hyaluronic acid levels can predict severe fibrosis and platelet counts can predict cirrhosis in patients with nonalcoholic fatty liver disease. J. Gastroenterol. Hepatol. 21, 1459-1465 (2006).
97. Nobili, V. et al. Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease. Gastroenterology 136, 160-167 (2009).
98. Ratziu, V. et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 6, 6 (2006).
99. Sakugawa, H. et al. Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. World J. Gastroenterol. 11, 255-259 (2005).
100. Santos, V. N. et al. Serum laminin, type IV collagen and hyaluronan as fibrosis markers in non-alcoholic fatty liver disease. Braz. J. Med. Biol. Res. 38, 747-753 (2005).
101. Suzuki, A. et al. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease. Liver Int. 25, 779-786 (2005).
102. Johansen, J. S. et al. Serum YKL?40 is increased in patients with hepatic fibrosis. J. Hepatol. 32, 911-920 (2000).
103. Malik, R. et al. The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease. J. Gastroenterol. Hepatol. 24, 564-568 (2009).
104. Rosenberg, W. M. et al. Serum markers detect the presence of liver fibrosis: A cohort study. Gastroenterology 127, 1704-1713 (2004).
105. Adams, L. Transient elastography in nonalcoholic fatty liver disease: making sense of echoes. Hepatology 51, 370-372 (2010).
106. Castera, L. et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 128, 343-350 (2005).
107. Poynard, T. et al. Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers. PLoS ONE 3, e3857 (2008).
108. Ngo, Y. et al. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin. Chem. 52, 1887-1896 (2006).
109. Naveau, S. et al. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology 49, 97-105 (2009).
110. Parkes, J. et al. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut 59, 1245-1251 (2010).
111. Nunes, D. et al. Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection. Am. J. Gastroenterol. 105, 1346-1353 (2010).
112. Vergniol, J. et al. Noninvasive tests for fibrosis and liver stiffness predict 5?year outcomes of patients with chronic hepatitis C. Gastroenterology 140, 1970-1979 (2011).
113. Robic, M. A. et al. Liver stiffness accurately predicts portal hypertension related complications in patients with chronic liver disease: A prospective study. J. Hepatol. 55, 1017-1024 (2011).
114. Kim, D., Kim, W. R., Kim, H. J. & Therneau, T. M. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 57, 1357-1365 (2013).
115. Treeprasertsuk, S., Bjornsson, E., Enders, F., Suwanwalaikorn, S. & Lindor, K. D. NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients. World J. Gastroenterol. 19, 1219-1229 (2013).
116. Castera, L. & Pinzani, M. Biopsy and non-invasive methods for the diagnosis of liver fibrosis: does it take two to tango? Gut 59, 861-866 (2010).